Lifecore Biomedical (FRA:LDE) ROCE %: -14.77% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:LDE Lifecore Biomedical Inc FRA:LDE
58 GF Score
Price €3.98
GF Value €5.64
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Lifecore Biomedical ROCE %?

Lifecore Biomedical FRA:LDE -2.45% 58 ROCE % is -14.77% as of Mar. 2026. GuruFocus rates FRA:LDE with a GF Score™ of 58/100 and a GF Value™ of €5.64 (Modestly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lifecore Biomedical's annualized ROCE % for the quarter that ended in Mar. 2026 was -14.77%.

Lifecore Biomedical  (FRA:LDE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lifecore Biomedical ROCE % Related Terms

Lifecore Biomedical ROCE % Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical ROCE % Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.08 -2.33 -29.41 12.92 -7.62

Lifecore Biomedical Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.39 8.76 -6.19 0.00 -14.77
FRA:LDE
58GF Score
Lifecore Biomedical Inc FRA:LDE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical ROCE % Calculation

Lifecore Biomedical's annualized ROCE % for the fiscal year that ended in May. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: May. 2025 )  (A: May. 2024 )(A: May. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: May. 2025 )  (A: May. 2024 )(A: May. 2025 )
=-14.641/( ( (234.913 - 35.957) + (212.296 - 26.768) )/ 2 )
=-14.641/( (198.956+185.528)/ 2 )
=-14.641/192.242
=-7.62 %

Lifecore Biomedical's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-26.256/( ( (198.279 - 20.131) + (195.057 - 17.73) )/ 2 )
=-26.256/( ( 178.148 + 177.327 )/ 2 )
=-26.256/177.7375
=-14.77 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -14.77% mean?
Lifecore Biomedical (FRA:LDE) has a ROCE % of -14.77% as of Mar. 2026.
Is Lifecore Biomedical's ROCE % too high?
Lifecore Biomedical's current ROCE % is -14.77%. Overall, Lifecore Biomedical has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's ROCE % compare to ANIK and DERM?
Lifecore Biomedical's ROCE % of -14.77% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.04. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current ROCE % is -14.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (FRA:LDE) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.64, compared to a current price of €3.98 — trading 29.4% below its estimated fair value. The current ROCE % is -14.77%. Lifecore Biomedical's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Lifecore Biomedical (FRA:LDE), the current ROCE % is -14.77% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lifecore Biomedical (FRA:LDE) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of €3.98 is trading 29.4% below its estimated GF Value™ of €5.64. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for FRA:LDE:

  • ROCE %: -14.77%
  • GF Value™: €5.64 vs. price of €3.98 (29.4% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the FRA:LDE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lifecore Biomedical Business Description

Other Exchanges LFCR:USA
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
58GF Score

Get the complete analysis for FRA:LDE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.98
Price
€5.64
GF Value